SEARCH

SEARCH BY CITATION

References

  • 1
    Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy 2005; 51: 122.
  • 2
    Gregg CR. Enteric bacterial flora and bacterial overgrowth syndrome. Semin Gastrointest Dis 2002; 13: 2009.
  • 3
    Sherman P, Lichtman S. Small bowel bacterial overgrowth syndrome. Dig Dis 1987; 5: 15771.
  • 4
    Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 1999; 94: 132731.
    Direct Link:
  • 5
    Henriksson AE, Blomquist L, Nord CE, et al. Small intestinal bacterial overgrowth in patients with rheumatoid arthritis. Ann Rheum Dis 1993; 52: 50310.
  • 6
    Drenick EJ, Johnson D. Hepatic steatosis after intestinal bypass-prevention and reversal metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982; 82: 53548.
  • 7
    Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol 2008; 6: 75964.
  • 8
    Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292: 8528.
  • 9
    Parodi A, Dulbecco P, Savarino E, et al. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. J Clin Gastroenterol 2009; 43: 9626.
  • 10
    Pimentel M, Park S, Mirocha J, et al. The effect of nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145: 55763.
  • 11
    Posserud I, Stotzer PO, Björnsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007; 56: 8028.
  • 12
    Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systemic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 127986.
  • 13
    Grover M, Kanazawa M, Palsson OS, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress. Neurogastroenterol Motil 2008; 20: 9981008.
  • 14
    Corazza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology 1990; 98: 3029.
  • 15
    Peralta S, Cottone C, Doveri T, et al. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with rifaximin. World J Gastroenterol 2009; 15: 262831.
  • 16
    Parodi A, Capurso G, Perri F, et al. H2-breath testing for small-intestinal bacterial overgrowth. Aliment Pharmacol Ther 2009; 29(Suppl. 1): 1826.
  • 17
    Majewski M, McCallum RW, Sostarich S, et al. Efficacy of rifaximin, a nonabsorbed oral antiobiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci 2007; 333: 26670.
  • 18
    Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 22: 315.
  • 19
    Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007; 25: 7816.
  • 20
    Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs 2009; 18: 34958.
  • 21
    Parodi A, Sessarego M, Greco A, et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 2008; 103: 125762.
    Direct Link:
  • 22
    Ellen L. Bacterial overgrowth. In: YamadaT, AlpersDH, KaplowitzN, LaineL, OwyangC, PowelDW (eds). Textbook of Gastroenterology. 4th edn. Philadelphia: JB Lippincott, 2003: Vol. 2, 161725.
  • 23
    Resmini E, Parodi A, Savarino V, et al. Evidence of prolonged orocecal transit time and small intestinal bacterial overgrowth in acromegalic patients. J Clin Endocrinol Metab 2007; 92: 211924.
  • 24
    Lauritano EC, Bilotta AL, Gabrielli M, et al. Association between hypothyroidsm ans small intestinal bacterial overgrowth. J Clin Endocrinol Metab 2007; 92: 41804.
  • 25
    Latella G, Pimpo MT, Sottili S, et al. Rifaximin improbe symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003; 18: 5562.
  • 26
    Papi C, Ciaco A, Koch M, et al. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo controlled trial. Aliment Pharcol Ther 1995; 3: 339.
  • 27
    Di Mario F, Aragona G, Leandro G, et al. Efficacy of mesalaxine in the treatment of symptomatic diverticular disease. Dig Dis Sci 2005; 50: 5816.
  • 28
    Lauritano EC, Gabrielli M, Scarpellini E, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009; 13: 1116.
  • 29
    Muller-Lissner SA. Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta-analysis. Br Med J 1988; 296: 6157.
  • 30
    Stephen AM, Cummings JH. Mechanism of action of dietary fibre in the human colon. Nature 1980; 284: 2834.
  • 31
    Bijkerk CJ, Muris JW, Knottnerus JA, et al. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19: 24551.
  • 32
    Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for a reappraisal. Lancet 1994; 344: 3940.
  • 33
    Lina BAR. Sub-Chronic (13 Week) Oral Toxicity Study With Sunfiber and Sunfiber ST in Rats. TNO report V97.080. Amsterdam: TNO Nutrition and Food Research Institute, 1997.
  • 34
    Takahashi H, Yamamoto T. Effect of partially hydrolyzed guar gum on fecal output in human volunteers. Nutr Res 1993; 13: 64957.
  • 35
    Giaccari S, Grasso G, Tronci S, et al. Gomma guar parzialmente idrolizzata: una fibra come coadiuvante nella sindrome del colon irritabile. Clin Ter 2001; 152: 215.
  • 36
    Giannini EG, Mansi C, Dulbecco P, et al. Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. Nutrition 2006; 22: 33442.
  • 37
    Takahashi H, Yamamoto T. Influence of partially hydrolyzed guar gum on constipation in women. J Nutr Sci Vitaminol 1994; 40: 2517.
  • 38
    Tuohy KM, Gibson GR. The prebiotic effects of biscuits containing partially hydrolyzed guar gum and fructo-oligosaccharides-a human volunteer study. Br J Nutr 2001; 86: 3418.
  • 39
    Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microflora-introducing the concept of prebiotics. J Nutr 1995; 125: 140112.
  • 40
    Weaver GA, Tangel C, Krause JA, et al. Dietary guar gum alters colonic microbial fermentation in azoxymethane-treated rats. J Nutr 1996; 126: 197981.
  • 41
    Okubo T, Ishihara T, Takahashi H, et al. Effects of partially hydrolyzed guar gum intake on human intestinal microflora and its metabolism. Biosci Biotechnol Biochem 1994; 58: 13649.
  • 42
    Lupp C, Robertson ML, Wickham ME, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007; 2: 204.
  • 43
    Philips SF. Physiology and pathophysiology of the colon: relationship to constipation. In: BarbaraL, StanghelliniV, eds. Chronic Constipation. London: WB Saunders; 1996, pp. 1937.
  • 44
    Riordan SM, McIver CJ, Walker BM, et al. The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol 1996; 91: 1795803.
  • 45
    Rocco A, De Martino G, De Nucci G, et al. Intra-individual reproducibility of the glucose hydrogen breath test in a cohort of healthy subjects. Dig Liver Dis 2010; 42(Suppl. 2): 118.
  • 46
    Lombardo L, Foti M, Ruggia O, et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010; 8: 5048.